Extended Data Table 7 Additional safety parameters in the safety analysis set

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  1. TEAE, treatment-emergent adverse event.
Back to article page